Kornimate/medical-research-clean huggingface dataset:
accuracy of ediagepu, a medical computerized tool for epu

Conditions: Pregnant Women Less Than 14 Weeks of Gestation

Summary: in a recently published study, a poor knowledge of guidelines in the field of early pregnancy was observed in france, belgium and switzerland. to improve the respect of the most recent criteria of diagnoses, a computerized tool was developped.

in december 2018, the investigators published an prospective multinational survey, with 17 questions that assessed the participants' knowledge, interest, and management of early pregnancy in france, belgium and switzerland1. knowledge about early management of pregnancy was limited among the practitioners surveyed ; 211/306 (69.0%) participants reported incorrect management when they visualized a gestational sac without embryo and 265/306 (86.6%) misinterpreted changes in serum levels of chorionic gonadotropin during early pregnancy. to fill this gap, the investigators developped a computerized tool who is following strictly the most recent criteria of diagnoses in the field of early pregnancy. this tool should be evaluated in an observational study, using data of real patients without modification of their management.

Eligibility criteria:
inclusion criteria: * pregnancy of unknown location (hcg + without gestational sac found in ultrasound) * viable pregnancy with embryo less than 14 weeks of gestation * non-viable pregnancy ; ectopic pregnancy, complete, incomplete or missed miscarriage exclusion criteria: - incomplete follow up and no diagnosis and lack of data to establish a diagnosis

Keywords: viable pregnancy miscarriage ectopic pregnancy early pregnancy
low-dose venetoclax and azacitidine as front-line therapy in newly diagnosed aml

Conditions: AML

Summary: venetoclax plus azacitidine are effective in treating newly diagnosed aml in patients who cannot recieve intensive chemotherapy. however there is no clinical data rewarding the efficacy and safety of low-dose venetoclax and azacitidine as first-line therapy.

venetoclax plus azacitidine are effective in treating newly diagnosed aml in patients who cannot recieve intensive chemotherapy. however there is no clinical data rewarding the efficacy and safety of low-dose venetoclax and azacitidine as first-line therapy. this phase 2 clinical trial will explore the efficacy and safety of low-dose venetoclax (100mg /day/21 days) and a fixed dose of azacitidine (75mg/m2, maximun dose 100mg, sc for seven consecutive days) for a maximun of two cycles.

Eligibility criteria:
inclusion criteria: 1. age \>18 years 2. both genders 3. diagnosis of non-m3 aml by the who 2016 diagnostic criteria 4. patients eligible and not eligible for transplant 5. aml secondary to treatment or associated to myelodisplasia exclusion criteria: 1. aml with pml/rar-alfa translocation t(15;17) 2. central nervous system involvement 3. poor functional status (ecog\>2) 4. organic dysfunction (marshall score ≥2) 5. active infection 6. use of other cyp3a4 inhibitors 7. pregnancy 8. gfr \<30 ml/min/1.72m2

Keywords: acute myeloid leukemia venetoclax azacitidine first-line therapy induction chemotherapy
multi-center, single arm, observational study to evaluate the safety of dapagliflozin in type 2 diabetes mellitus patients in china

Conditions: Type 2 Diabetes Mellitus

Summary: donate study is a multi-center, prospective cohort, single arm, observational study to be performed in 3000 chinese type 2 diabetes mellitus (t2dm) patients recruited from 100 tier 2 or 3 hospitals, china.it is a drug intense monitoring study required by china food and drug administration (cfda) to assess the newly approved drug in at least 3000 patients within the first five years after commercial launch. the primary objective is to demonstrate the safety of dapagliflozin by assessment of the incidence of adverse events and serious adverse events during 6-month follow up in chinese patients with t2dm.


Eligibility criteria:
inclusion criteria: * provision of subject informed consent prior to any study specific procedures. * chinese, female or male. * t2dm diagnosed by physicians according to 2013 chinese guideline for diabetes, ie. 1) patients with typical syndrome and with a fpg ≥ 7.0mmol/l and/or random plasma glucose ≥ 11.1mmol/l; and/or, 2) patients without typical syndrome and with repeated fpg ≥ 7.0mmol/l and/or 2 hour post challenged plasma glucose ≥ 11.1mmol/l. * subjects who already took at least one dose of dapagliflozin, which is prescribed by physicians based on their clinical practice. the prescription of dapagliflozin is separated from the decision to be included in the current study or not. exclusion criteria: * being unable to comply with study-specified procedures. * participating in any other clinical trial currently or during the last 3 months. * previous enrolment in the present study.
shorter scalp cooling time in paclitaxel

Conditions: Neoplasm Malignant; Breast Cancer; Ovarian Cancer

Summary: chemotherapy-induced alopecia (cia) is one of the most distressing side effects for patients. scalp cooling can prevent or minimise cia in approximately half of all patients, depending on many factors, e.g. type and dosage of chemotherapy. high rates of success are seen in patients treated with taxanes, up to 80-90%. previous research has shown comparable results of scalp cooling in docetaxel-treated patients when shortening the post-infusion cooling time (pict) from the initial standard of 90 minutes to 45- and 20 minutes. a shorter pict is an advantage for both the patient, who can spend less time in the hospital, as well for the logistics at oncological departments. paclitaxel and docetaxel are both classical taxanes, that share similar mechanisms of action and have comparable plasma terminal half-life times, therefore it seems plausible that the pict can be shortened for paclitaxel-treated patients as well.


Eligibility criteria:
inclusion criteria: * patients receiving weekly-administered paclitaxel-containing chemotherapy (minimal 3 planned administrations) in a dose of 80-90 mg/m2 paclitaxel monotherapy, paclitaxel in combination with carboplatin, paclitaxel in combination with monoclonal antibodies: bevacizumab or trastuzumab * age ≥ 18 years * who performance status 0-2 * survival expectation must be \> 3 months * written informed consent according to the local ethics committee requirements exclusion criteria: * treatment with paclitaxel in sequential schemes with other alopecia inducing agents such as paclitaxel monotherapy after adriamycin, cyclophosphamide (ac) or paclitaxel monotherapy after 5-fluouracil, epirubicin, cyclophosphamide (fec) treatment * alopecia before the start of the study * rare cold-related disorders: cold sensitivity, cold agglutinin disease, cryoglobulinaemia, cryofibrinogenaemia, cold posttraumatic dystrophy

Keywords: paclitaxel-containing chemotherapy
the treatment of lenalidomide in patients with poems syndrome

Conditions: POEMS Syndrome

Summary: lenalidomide is a immunomodulatory drug derived from thalidomide, without neurotoxicity. lenalidomide blocks the increased secretion of interleukin-6, tumor necrosis factor alpha and vascular endothelial growth factor (vegf). the association with dexamethasone increased lenalidomide response rate. more recently the efficacy of lenalidomide has been reported in a patient with poems (poems:polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome with improvement of clinical condition and reduction of vascular endothelial growth factor (vegf) and interleukin-6 (il-6) level.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of poems syndrome based on published diagnostic criteria exclusion criteria: * any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
development and content validation of the childhood early oral aging syndrome (ceoas) index for the deciduous dentition

Conditions: Aging

Summary: premature, non-physiological tooth wear in childhood has numerous repercussions for oral health. this is a growing problem with multifactorial causes and associated with the current lifestyle. the aim of the present study was the development and determination of content validity of the childhood early oral aging syndrome (ceoas) index for the primary dentition as a diagnostic and epidemiological survey tool considering the current changes found in this population.


Eligibility criteria:
inclusion criteria: -dental surgeons exclusion criteria: -other healthcare professionals
neural gliding exercise for low back pain

Conditions: Low Back Pain

Summary: low back pain is a very common problem that causes pain, disability, gait and balance problems. neurodynamic techniques is used for treatment of low back pain. the aim of the study is comparing the effects of electrotherapy and neural mobilization techniques on pain, functionality, gait and balance.

there are many physiotherapy modalities in the treatment of low back pain (lbp). electrotherapy procedures, manual therapy techniques, kinesiotherapy and specific exercises are among those that are frequently used. in neural mobilization techniques, which began to gain popularity in 1990s, neural tissue and the surrounding structures are glided or tensioned to mobilize them. neural mobilization is thought to have a positive effect on symptoms by inducing intraneural circulation, axoplasmic flow, and neural visco-elasticity and sensitivity associated with the connective tissue. there are studies in which this modality has yielded therapeutic success in terms of both pain and functionality, particularly in lumbar region and lower limb disorders where neural mechanosensitivity is increased.

Eligibility criteria:
inclusion criteria: * subjects scoring below 70 degrees in the straight leg raise test * received no physiotherapy until at least 6 months before initial evaluation exclusion criteria: * subjects who were unable to walk independently, * who had systemic diseases besides lbp, * who underwent spinal and lower limb surgery, * who scored above 70 degrees in the straight leg raise test, * used analgesics within 48 hours before initial evaluation were excluded.

Keywords: low back pain neurodynamics
voriconazole (vfend) drug use investigation (regulatory post marketing commitment plan)

Conditions: Systemic Mycosis

Summary: to collect the efficacy and safety informations of voriconazole related to their appropriate use in daily practice.

all the subjects whom an investigator prescribes the first voriconazole (vfend) should be registered consecutively until the number of subjects reaches target number in order to extract subjects enrolled into the investigation at random.

Eligibility criteria:
inclusion criteria: * male or female subjects intend to treat their deep mycosis who are prescribed voriconazole (vfend) by their physicians. exclusion criteria: * subject who heve been prescribed voriconazole (vfend) before.

Keywords: systemic mycosis aspergillus infection candidiasis cryptococcal infections japanese voriconazole vfend regulatory post marketing commitment plan.
weight-bearing measuring device following anterior cruciate ligament reconstruction

Conditions: Weight-bearing Deficits

Summary: the objective of this clinical trial is to in determining weight-bearing deficits following anterior cruciate ligament reconstruction.

orthopedic surgeons and rehabilitation physicians frequently request limited weight-bearing for prolonged periods following certain bony or soft tissue pathologies as well as certain lower - limb surgical procedures. walking, stair climbing, jogging, elliptical training and running on treadmill are a common activity that the injured athlete will seek to return to as soon as possible following injury or surgery. in order for the physician to be able to advise regarding weight-bearing, the percentage body-weight/weight-bearing (pbw/wb) values in increasing walking, jogging speeds, elliptical training must be known. these parameters as well as the gait distribution changes have eluded the rehabilitation community, mainly due to the technical inability to measure these paradigms. there are no short-term studies quantifying weight-bearing deficits as well as weight-bearing gait distribution characteristics following anterior cruciate ligament reconstruction (aclr). furthermore, there are no published studies that have investigated whether differences exist between various surgical procedures and replacement graft choices in the acute- phase (0-3 weeks) post surgery descriptive clinical trial. during their regular training the participants will use the flexible, light weight, force-sensing insole for few minutes to receive the parameters 30 subjects. the test subjects will be instructed to walk at their normal speed on a solid ground surface over a distance of 16 meters. the results will be analyzed and a table of normal values will be established including average pbw/wb values for the entire, hind and fore-foot as well as gait distribution changes.

Eligibility criteria:
inclusion criteria: * male or female patients more than 18 years old, derivate to physiotherapy treatment in lerner central sport, hebrew university - jerusalem * patients who are willing to participate in the trial and to sign the informed consent forms. exclusion criteria: * patients receiving other methods of treatment to this area, * patients with concomitant other injury of the hip, knee, ankle or foot. * non cooperative patient.

Keywords: weight bearing acl
plaque control efficacy between interdental brushes versus dental floss

Conditions: Periodontal Diseases; Dental Plaque

Summary: the purpose of this study is to compare between plaque control efficacy of interdental brushes versus interdental floss , for the prevention of periodontal disease (gingivitis) and to determine the most convenient routine interdental plaque control method amongst the two


Eligibility criteria:
inclusion criteria: * all patients above 18 years of age with gingivitis * patients of both gender exclusion criteria: * patients who refuse participate in the study * patients with systemic medical problems * patients using medications that may affect gingival tissue (overgrowth/bleeding) * patients habitual of betel nut/tobacco smoking/substance abuse * patients with fluorosis or any other enamel and dentinal deformity * pregnant women * patients undergoing orthodontic treatment
a study on the effects of exercise on side effects from treatment for gastrointestinal cancers

Conditions: Gastrointestinal Cancer

Summary: the purpose of this study is to find the level of aerobic exercise (at) that is practical, is safe, and has positive effects on the body that may reduce the side effects of therapy. the study will also look at the way the body responds to exercise and whether there are differences in treatment. this will include looking at the highest treatment dose participants receive, how many people stop, delay, or reduce the treatment, and whether additional medication is needed to treat side effects of therapy.


Eligibility criteria:
inclusion criteria: * aged ≥18 years * diagnosed with locally advanced colorectal or esophago/gastric solid tumors as defined by one of the following: * histological confirmation * as per standard of care imaging * scheduled to receive neoadjuvant chemotherapy * performing ≤90 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report * willingness to comply with all study-related procedures * cleared for exercise participation as per screening clearance via the physical activity readiness questionnaire exclusion criteria: * enrollment onto any other interventional investigational study, except interventions determined by the pi not to confound study outcomes * receiving treatment for any other diagnosis of invasive cancer * distant metastatic malignancy of any kind * mental impairment leading to inability to cooperate * any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation

Keywords: exercise 22-164
a comparative ct evaluation of the amount of root resorption in self-ligating versus conventional brackets

Conditions: Root Resorption

Summary: aim: the aim of the study was to evaluate and compare the extent of root resorption in the maxillary and mandibular anterior teeth during orthodontic treatment with the use of different types of brackets. materials and methods: the study consisted of 21 patients (11 males and 10 females) within the age group of 16-25 years, having bimaxillary protrusion. they were divided into three groups. in group 1- conventional brackets, group 2- self-ligation brackets:smart clip (passive), and in group 3 self-ligation brackets: empower (active) were bonded. computed tomography scans and orthopantomograms were taken before start of treatment and after six months of retraction. root resorption is computed as the difference between the pre treatment total tooth length and the post treatment total tooth length.


Eligibility criteria:
inclusion criteria: - patients having complete root formation at start of treatment, exclusion criteria: * patients with skeletal or dental anomalies . * patients having history of root resorption * patients having any systemic or metabolic anomalies, * patients with trauma of anterior teeth * patients with periapical inflammation of the anterior teeth * patients with impacted teeth * patients with tumors and cysts in the examined area * patients having undergone orthodontic treatment previously.
study of proton pump inhibitors (ppi) to prevent strictures after gastric bypass surgery

Conditions: Anastomotic Stricture; Morbid Obesity

Summary: the purpose of this study is to determine whether suppressing acid production by administration of daily proton pump inhibitors in the early post-operative period will reduce the gastrojejunal anastomosis stricture rate in patients undergoing laparoscopic gastric bypass surgery for morbid obesity.

laparoscopic roux-en-y gastric bypass (lyrgb) has been shown to be a safe and effective procedure for the treatment of morbid obesity. however, a common early complication of lyrgb is stricture at the gastrojejunal (gj) anastomosis, occurring in 4% - 27% of patients, usually within the third post-operative month. this complication usually presents with progressive dysphagia leading to daily vomiting. endoscopic balloon dilation is the treatment of choice for this complication, and multiple dilations are often required to provide complete resolution. the etiology of gj anastomotic strictures is unknown and is probably multi-factorial. some investigators hypothesize that ischemia or non-ischemia-related excessive scar formation is the cause of stricture. the method of construction of the anastomosis as well seems to have an impact, as circular stapled anastomoses may have higher rates of stricture than linear staplers or completely hand-sewn anastomoses. the route of the roux limb (antecolic vs retrocolic) does not appear to affect this complication. several investigators have demonstrated little acid production in the gastric bypass pouch. despite this data, acid secretion has been hypothesized as a predominant factor in the development of gj stricture. this hypothesis is supported in part by the frequent finding of ulcers at the site of stricture in up to 55% of patients. the purpose of this study is to determine whether suppressing acid production by administration of daily proton pump inhibitors in the early post-operative period will reduce gj anastomosis stricture rate. please note: this study does not provide surgery (appropriate insurance coverage is required).

Eligibility criteria:
inclusion criteria: * any patient who satisfies the requirements of the weill-cornell weight loss surgery program to undergo laparoscopic roux-en-y gastric bypass surgery as treatment for morbid obesity. exclusion criteria: * patients with a history of ulcer disease, patients taking chronic acid suppression medicine, and patients taking nsaids.

Keywords: gastric bypass anastomotic stricture morbid obesity bariatric surgery omeprazole
efficacy and safety of sacubitril/valsartan in maintenance hemodialysis patients with heart failure

Conditions: Hemodialysis Complication; Heart Failure

Summary: sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction, and has been recently indicated as a new treatment option with a strong level of recommendation (class i, level of evidence b) in the main international guidelines. cardiovascular disease (cvd) is the most common cause of death in end stage renal disease (esrd) patients undergoing hemodialysis (hd). hence, treatments to improve mortality and specifically cardiovascular outcomes in this population are greatly needed. so far, no data available about the efficacy and safety of sacubitril/valsartan in esrd patients undergoing hemodialysis, although this medication was noted to be effective and comparably well tolerable in those with estimated glomerular filtration rate(egfr) 20 to 60 ml/min/1.73 m2 in the united kingdom heart and renal protection-iii trial. the purpose of this open label, randomized controlled study with prospective data collection is to assess the efficacy and safety of sacubitril/valsartan in maintenance hemodialysis patients with heart failure.


Eligibility criteria:
inclusion criteria: * written informed consent obtained before any study assessment is performed. * end stage renal disease (esrd) patients (egfr\<15ml/min/1.73m² as measured by the chronic kidney disease epidemiology collaboration formula at screening) who have been receiving hemodialysis 3 times a week for at least 12 weeks before registration. * chronic heart failure (nyha class ≥ ii) with reduced ejection fraction, defined as known lvef ≤ 50%. * mean sitting systolic blood pressure(mssbp)≥110 mmhg. * use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker for at least 2 weeks. * good compliance. exclusion criteria: * acute renal failure with hemodialysis. * isolated right heart failure owing to pulmonary disease, primary cause of dyspnea due to noncardiac, non-hf causes such as acute or chronic respiratory disorders. * systolic blood pressure lower than 100 mmhg at screening (\<95 mmhg at the randomization visit). * previous history of intolerance to recommended target doses of angiotensin receptor blockers. * significant laboratory abnormalities at screening interfering with assessment of study drug safety or efficacy (such as serum potassium\>5.5 or \ 2 times the upper limit of the normal range) * history of hypersensitivity to any of the study drugs or their excipients or to drugs of similar chemical classes. * history of angioedema. * any medications that have potential for drug-drug interaction with lcz696 will not be allowed during the study. * pregnant female. * use of sacubitril/valsartan prior to week-2.

Keywords: sacubitril/valsartan valsartan hemodialysis heart failure